ALNYNASDAQ— Alnylam Pharmaceuticals Inc Price & Analysis

Alnylam Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$224.03

-$3.25-1.43%

Market Cap: $30.41B; Large Cap
P/E Ratio: 38.33; Fwd: 19.68
EPS (TTM): $5.93
Div. Yield: N/A

Technical Summary

RSI (14)41.73Neutral

SMA (50)$239.05Bearish

SMA (200)$289.88Bearish

MACD-4.1906Bullish

Bollinger$210.79 – $250.62Mid

Stochastic40.92Neutral

Theo Outlook

Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing and commercializing RNA interference therapies. For the trailing twelve months it reported revenue of $4.80 billion, a profit margin of 16.1 percent, earnings per share of $5.93 and a market capitalization of $30.41 billion as of the quarter ended June 30, 2026.

Bull case: quarterly revenue grew 66.9 percent year over year, return on equity reached 96.6 percent and EBITDA stood at $1.05 billion. Bear case: the trailing price-to-earnings ratio is 38.33, the price-to-book ratio is 24.87 and the enterprise value to revenue multiple is 6.58.

Main risks include the 0.269 beta and dependence on product development in a competitive biotechnology sector. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Fundamental Snapshot

Revenue: $4.80B
EBITDA: $1.05B
Gross Profit: $3.83B
Operating Margin: 17.9%
Profit Margin: 16.1%
ROE: 96.6%
Book Value: $10.12
Beta: 0.27
52-Wk High: $485.36
52-Wk Low: $197.81
Volume: 1.00M
PEG Ratio: 0.33

Frequently Asked Questions

What does Alnylam do?

Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing and commercializing RNA interference therapies. It is headquartered in Cambridge, Massachusetts.

Where does Alnylam's revenue come from?

Alnylam reported trailing twelve month revenue of $4.80 billion as of June 30, 2026. Quarterly revenue grew 66.9 percent year over year in the latest period.

How does Alnylam compete?

Alnylam operates in the biotechnology industry with a focus on RNAi therapies. It achieved a gross profit of $3.83 billion and an operating margin of 17.9 percent over the trailing twelve months ended June 30, 2026.

What are the main risks for Alnylam?

Alnylam faces risks typical of biotechnology companies including product development outcomes. Its beta of 0.269 indicates lower volatility relative to the market as of the latest data.

How is Alnylam valued?

Alnylam trades at a trailing price-to-earnings ratio of 38.33, a forward price-to-earnings ratio of 19.68 and a price-to-book ratio of 24.87. The enterprise value to revenue multiple is 6.58 and the enterprise value to EBITDA multiple is 28.62 based on the most recent figures.